TY - JOUR
T1 - Fractional anisotropy derived from the diffusion tensor distribution function boosts power to detect Alzheimer's disease deficits
AU - for the Alzheimer's Diseaase Neuroimaginng Initiative (ADNI)
AU - Nir, Talia M.
AU - Jahanshad, Neda
AU - Villalon-Reina, Julio E.
AU - Isaev, Dmitry
AU - Zavaliangos-Petropulu, Artemis
AU - Zhan, Liang
AU - Leow, Alex D.
AU - Jack, Clifford R.
AU - Weiner, Michael W.
AU - Thompson, Paul M.
N1 - Funding Information:
Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroIm-mun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neuro-track Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California–San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding for the ENIGMA Center for Worldwide Medicine Imaging and Genomics is provided as part of the BD2K Initiative under grant number U54 EB020403 to support big data analytics.
Funding Information:
Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California–San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding for the ENIGMA Center for Worldwide Medicine Imaging and Genomics is provided as part of the BD2K Initiative under grant number U54 EB020403 to support big data analytics. Many of the ADNI investigators contributed to the design and implementation of ADNI and/or provided data, but most of them did not participate in this analysis or help write this report. A complete list of ADNI investigators is available at https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Publisher Copyright:
© 2017 International Society for Magnetic Resonance in Medicine
PY - 2017/12
Y1 - 2017/12
N2 - Purpose: In diffusion MRI (dMRI), fractional anisotropy derived from the single-tensor model (FADTI) is the most widely used metric to characterize white matter (WM) microarchitecture, despite known limitations in regions with crossing fibers. Due to time constraints when scanning patients in clinical settings, high angular resolution diffusion imaging acquisition protocols, often used to overcome these limitations, are still rare in clinical population studies. However, the tensor distribution function (TDF) may be used to model multiple underlying fibers by representing the diffusion profile as a probabilistic mixture of tensors. Methods: We compared the ability of standard FADTI and TDF-derived FA (FATDF), calculated from a range of dMRI angular resolutions (41, 30, 15, and 7 gradient directions), to profile WM deficits in 251 individuals from the Alzheimer's Disease Neuroimaging Initiative and to detect associations with 1) Alzheimer's disease diagnosis, 2) Clinical Dementia Rating scores, and 3) average hippocampal volume. Results: Across angular resolutions and statistical tests, FATDF showed larger effect sizes than FADTI, particularly in regions preferentially affected by Alzheimer's disease, and was less susceptible to crossing fiber anomalies. Conclusion: The TDF “corrected” form of FA may be a more sensitive and accurate alternative to the commonly used FADTI, even in clinical quality dMRI data. Magn Reson Med 78:2322–2333, 2017.
AB - Purpose: In diffusion MRI (dMRI), fractional anisotropy derived from the single-tensor model (FADTI) is the most widely used metric to characterize white matter (WM) microarchitecture, despite known limitations in regions with crossing fibers. Due to time constraints when scanning patients in clinical settings, high angular resolution diffusion imaging acquisition protocols, often used to overcome these limitations, are still rare in clinical population studies. However, the tensor distribution function (TDF) may be used to model multiple underlying fibers by representing the diffusion profile as a probabilistic mixture of tensors. Methods: We compared the ability of standard FADTI and TDF-derived FA (FATDF), calculated from a range of dMRI angular resolutions (41, 30, 15, and 7 gradient directions), to profile WM deficits in 251 individuals from the Alzheimer's Disease Neuroimaging Initiative and to detect associations with 1) Alzheimer's disease diagnosis, 2) Clinical Dementia Rating scores, and 3) average hippocampal volume. Results: Across angular resolutions and statistical tests, FATDF showed larger effect sizes than FADTI, particularly in regions preferentially affected by Alzheimer's disease, and was less susceptible to crossing fiber anomalies. Conclusion: The TDF “corrected” form of FA may be a more sensitive and accurate alternative to the commonly used FADTI, even in clinical quality dMRI data. Magn Reson Med 78:2322–2333, 2017.
KW - Alzheimer's disease
KW - diffusion-weighted imaging
KW - fractional anisotropy
KW - tensor distribution function
KW - white matter
UR - http://www.scopus.com/inward/record.url?scp=85014656008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014656008&partnerID=8YFLogxK
U2 - 10.1002/mrm.26623
DO - 10.1002/mrm.26623
M3 - Article
C2 - 28266059
AN - SCOPUS:85014656008
SN - 0740-3194
VL - 78
SP - 2322
EP - 2333
JO - Magnetic Resonance in Medicine
JF - Magnetic Resonance in Medicine
IS - 6
ER -